Skip to main content
. 2022 Jul 20;14(14):5855–5877. doi: 10.18632/aging.204189

Figure 5.

Figure 5

Astragalus and AS-IV enhanced PI3K/AKT pathway in vivo and vitro. (A and B) Expression level of Phospho-PI3K, PI3K, Phospho-AKT and AKT in kidney sections collected at 24 hours after CLP surgery following treatment with (250 mg/kg) Astragalus membranaceus or low (5 mg/kg) or high dosage (10 mg/kg) AS-IV. (C and D) Representative images showing Phospho-AKT immunohistochemical staining of mice kidney tissues. (E) Expression level of Phospho-PI3K, PI3K, Phospho-AKT and AKT in HK-2 cells incubated with LPS (1 μg/ml) plus AS-IV at the concentrations of 5, 10, 20 μM for 6 hours. (F) Protein expression of Phospho-PI3K, PI3K, Phospho-AKT and AKT in HK-2 cells incubated with LPS (1 μg/ml) plus AS-IV (20 μM) or PI3K inhibitor IC-87114 (5 μM) for 6 hours. (G) MTT results for AS-IV (20 μM) or PI3K inhibitor IC-87114 (5 μM) treatment on HK-2 cells incubated with LPS (1 μg/ml) for 6 hours. Data are presented as the mean ± SEM (n = 3 per group, *P < 0.05, **P < 0.01, ***P < 0.001).